Exelixis, Inc. 10-Q Summary: Quarter Ended March 30, 2007
Business Context and Reporting Period
This report covers the quarterly period ended March 30, 2007 (referred to as March 31, 2007 in financial tables). Exelixis, Inc. is a biopharmaceutical company focused on developing small molecule therapies for cancer and other serious diseases. The company operates primarily through drug discovery and development, supplemented by a German subsidiary providing transgenic mouse services. The company has no approved pharmaceutical products and relies on collaboration agreements for revenue.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Total Revenues | $28.1 million | $18.1 million |
| Net Loss | $(24.2) million | $(27.1) million |
| Net Loss Per Share (Basic/Diluted) | $(0.25) | $(0.32) |
| Operating Cash Flow | $44.8 million | $10.0 million |
| Cash and Cash Equivalents (End of Period) | $143.8 million | $140.1 million |
| Total Liquidity (Cash, Equivalents, Marketable Securities) | $305.9 million | Filing text does not provide clear Q1 2006 total liquidity figure |
| Debt Obligations (Notes, Bank, Convertible Loans) | $119.2 million | Filing text does not provide clear Q1 2006 total debt figure |
Note: Debt obligations include $13.5 million current portion of notes/bank obligations, $20.6 million long-term notes/bank obligations, and $85.0 million in convertible loans.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 55% to $28.1 million, driven by a $7.1 million increase in license revenue (amortization of upfront payments) and a $2.9 million increase in contract revenue. Key drivers included new upfront payments from Bristol-Myers Squibb ($60.0 million) and Genentech ($15.0 million) received in January 2007.
- Expense Increases: Research and Development (R&D) expenses rose 26% to $50.2 million, primarily due to increased clinical trial activity for compounds XL999, XL784, XL880, and XL647. General and Administrative (G&A) expenses increased 24% to $11.2 million due to higher personnel and stock-based compensation costs.
- Cash Flow Improvement: Net cash provided by operating activities surged to $44.8 million from $10.0 million, largely due to the timing of deferred revenue recognition from new collaboration deals and a significant decrease in other receivables.
- Investing Activities: The company shifted from a net cash provider in investing activities in 2006 to a net user in 2007 ($25.0 million used), primarily due to $61.6 million in purchases of marketable securities.
Guidance, Outlook, and Risks
Management Commentary and Outlook: Exelixis anticipates maintaining operations for at least 12 months following the filing date based on current cash, investments, and expected collaborator funding. However, the company expects to incur substantial losses for the foreseeable future. Management highlighted the achievement of "proof-of-concept" for compound XL647 in non-small cell lung cancer (NSCLC), which may trigger milestone payments from GlaxoSmithKline (GSK) but also obligates Exelixis to repurchase three compounds (XL647, XL999, XL784) from Symphony Evolution, Inc. (SEI).
Key Risks and Contingencies:
- SEI Repurchase Obligation: If GSK selects any of the SEI-licensed compounds for further development, Exelixis must repurchase all three. The repurchase price is the $80.0 million invested by SEI investors plus 25% per year. This could require significant additional capital or equity issuance.
- XL999 Clinical Hold: Previous clinical trials for XL999 were suspended due to cardiovascular adverse events. A new Phase 1 protocol was accepted by the FDA in April 2007, but future development remains uncertain.
- Liquidity Covenants: The company must maintain working capital of at least $25.0 million and cash/investments of at least $50.0 million to comply with its loan agreement with GSK. Failure to meet these covenants could result in immediate acceleration of debt.
- Capital Needs: Future capital requirements are substantial and depend on clinical trial outcomes and the timing of milestone payments.
Investor Verification Checklist
- Verify the status of GlaxoSmithKline's option to select XL647 for further development and the resulting financial impact of the mandatory SEI repurchase.
- Confirm the progress and safety data of the new FDA-approved Phase 1 trial for XL999 in NSCLC patients.
- Monitor compliance with GSK loan covenants (working capital >$25M; cash/investments >$50M) given the high burn rate of R&D.
- Assess the timeline for recognizing the $60.0 million Bristol-Myers Squibb and $15.0 million Genentech upfront payments as revenue over their respective terms.
- Review the company's ability to raise additional capital if the SEI repurchase option is triggered or if clinical trials face further delays.